Effectiveness of Adjuvant Supplements Prior to in IVF

Kaohsiung Veterans General Hospital.70 enrolled

Overview

To investigate the effect of combined DHEA, CoQ10 and tocotrienol on IVF cycles in poor ovarian responders

Background There is a trend for delayed marriage and childbearing worldwide. Women undergoing in vitro fertilization (IVF) cycles are getting older. Women with advanced age are more likely to be poor ovarian responders (PORs) who have poor prognosis in IVF cycles. Numerous studies have shown that DHEA supplementation may improve IVF outcomes in PORs. Additionally, due to poor prognosis of PORs, it is quite common to combine multiple therapies instead of just one treatment. Some studies showed that CoQ10 and tocotrienol are beneficial for fertility. Thus, the aim of this study is to investigate the effect of combined DHEA, CoQ10 and tocotrienol on IVF cycles in PORs. Objective To investigate the effect of combined DHEA, CoQ10 and Tocotrienol on PORs undergoing IVF cycles Methods The study will be conducted from March 1st, 2022 to December 31st, 2023 in our reproductive center. We plan to enroll 120 PORs undergoing IVF cycles and divided them into four groups: (1) DHEA (n=30): 75 mg DHEA supplementation per day for three months; (2) DHEA + CoQ10 + Tocotrienol (n=30): 75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for three months; (3) Control: no supplementation. Basic characteristics, infertility history, hormone profiles and ovarian reserve will be recorded. We will recheck serum levels of DHEA-S, FSH and AMH after DHEA supplementation. Then, during the IVF cycles, cumulus cells will be collected after oocyte retrieval to analyze genes expression and mitochondrial function. We will follow reproductive outcomes after embryo transfer. Outcome The effect of combined DHEA, CoQ10 and Tocotrienol on cumulus cells and IVF outcomes in PORs

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dietary Supplements

Interventions

DHEADIETARY_SUPPLEMENT

75 mg DHEA supplementation per day for 3 months before IVF

DHEA+CoQ10+TocotrienolDIETARY_SUPPLEMENT

75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF

Eligibility

Sex: FEMALEMin age: 35 YearsMax age: 44 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 35\~44 * BMI18\~30 kg/m2 * Diminished ovarian reserve (AFC\<5, AMH\<1.2 ng/ml) Exclusion Criteria: * Primary ovarian insufficiency * Congenital uterine anomaly * Severe intrauterine adhesion * Severe male factor * Chromosome anomaly * Malignancy * Donor cycle * having supplementation within 3 months

Locations (1)

Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

Kaohsiung City, Taiwan

Outcomes

Primary Outcomes

Ongoing pregnancy rate

continuous presence of a fetal heartbeat over 12 weeks of a pregnancy

Time frame: through study completion, an average of 1.75 year

Secondary Outcomes

Clinical pregnancy rate

the presence of a fetal heartbeat at 6-7 weeks of a pregnancy

Time frame: through study completion, an average of 1.75 year

mitochondrial function of cumulus cells

Oxygen consumption rate of cumulus cells

Time frame: through study completion, an average of 1.75 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.